Genetic Profile and Treatment of NSCLC
We recommend
Finding Balance Between Intracranial Efficacy and Adverse Effects of ALK Kinase Inhibition
More than 7 years – that is the current median survival of patients with non-small cell lung cancer (NSCLC) with a mutation in the anaplastic lymphoma kinase (ALK) gene who are receiving targeted therapy. Therefore, the quality of life of patients on treatment and the search for a balance between its antitumor efficacy and adverse effects (AEs) is becoming the focus of clinical research. Recently, lorlatinib has been discussed in this context.
Lorlatinib in a Patient with Meningeal Carcinomatosis – Case Report
The prognosis of patients with meningeal carcinomatosis is unfavorable. The following case report…
New ESMO Recommendations for Investigating Circulating Tumor DNA
Liquid biopsy has been discussed in oncology for several decades. As we move from conference…
Articles on this topic
Progress on Lorlatinib – What's Next?
Lorlatinib is currently mainly used in the 2nd and later lines of treatment for non-small cell…
Efficacy of Lorlatinib in Patients with ROS1-Positive NSCLC in Clinical Practice
Interesting real-world data have been brought by a study on the efficacy of lorlatinib in…
Update of the Blue Book: What's New in the Treatment of Metastatic NSCLC with an ALK Gene Mutation?
As of March 1, 2022, the 28th update of the Blue Book by the Czech Society for Oncology of ČLS…
Brain Metastases Are Not an Absolute Contraindication for Antiplatelet Therapy
On one hand, there's a higher risk of thromboembolic events, and on the other, a higher risk…
Complete remission of ALK-positive lung cancer in a patient after multiple lines of targeted therapy – a case study
Targeted treatment for driving oncogenic mutations has significantly improved outcomes for…
Genetic Profiling Transforms the Diagnosis and Treatment of Cancer Diseases
Genome sequencing provides doctors with more information about the causes of cancer diseases…
Screening using NGS in patients with metastatic NSCLC – initial results from the ALK-positive cohort
Next-generation sequencing (NGS) allows for obtaining a large amount of information about the…
Intracranial Activity of Lorlatinib in Patients with Metastatic ALK-Positive NSCLC
Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor with…
Lorlatinib showed significant benefit in 1st line treatment of advanced ALK-positive non-small cell lung carcinoma
In the international CROWN study, lorlatinib compared to crizotinib led to a 72% reduction in…
Genetic Testing in Non-Small Cell Lung Cancer - Clinical Practice Experience
Targeted therapy has brought significant improvements to certain groups of patients with…
1
2
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Screening using NGS in patients with metastatic NSCLC – initial results from the ALK-positive cohort
- Brain Metastases Are Not an Absolute Contraindication for Antiplatelet Therapy
- Update of the Blue Book: What's New in the Treatment of Metastatic NSCLC with an ALK Gene Mutation?
- Non-Small Cell Lung Cancer with Estrogen Receptors and ALK Positivity
- Progress on Lorlatinib – What's Next?
- Genetic Profiling Transforms the Diagnosis and Treatment of Cancer Diseases
Journal on this topic
Related topic